Selpercatinib Aimed at RET-Altered Cancers
Mené sur 105 patients atteints d'un cancer du poumon non à petites cellules présentant une fusion du gène RET, cet essai de phase I/II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du selpercatinib (durée médiane de suivi : 12,1 mois)
A remarkable increase has occurred in the number of highly targeted drugs that have efficacy in patients with advanced cancers that harbor specific genomic alterations. Prime examples are the NTRK inhibitors that target NTRK fusions, which are found in only approximately 0.3% of cancers.1,2 As many as 75% of the patients with tumors that bear NTRK fusions and who have received these agents have had a response. These results have led to the Food and Drug Administration (FDA) approval of the use of the NTRK inhibitors larotrectinib and entrectinib in adult and pediatric patients with NTRK fusion–positive solid tumors, regardless (...)
New England Journal of Medicine , éditorial, 2019